0000903423-19-000235.txt : 20190530
0000903423-19-000235.hdr.sgml : 20190530
20190530174738
ACCESSION NUMBER: 0000903423-19-000235
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190528
FILED AS OF DATE: 20190530
DATE AS OF CHANGE: 20190530
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC
CENTRAL INDEX KEY: 0001131399
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: X0
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38916
FILM NUMBER: 19867874
BUSINESS ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
BUSINESS PHONE: 011442080475000
MAIL ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc
CENTRAL INDEX KEY: 0001761612
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
BUSINESS PHONE: 011441223261503
MAIL ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
FORMER COMPANY:
FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd
DATE OF NAME CHANGE: 20181212
4
1
glaxo.xml
OWNERSHIP DOCUMENT
X0306
4
2019-05-28
0
0001761612
BICYCLE THERAPEUTICS plc
BCYC
0001131399
GLAXOSMITHKLINE PLC
980 GREAT WEST ROAD
BRENTFORD MIDDLESEX
X0
TW8 9GS
UNITED KINGDOM
1
0
1
0
Ordinary Shares
2019-05-28
4
C
0
893195
A
893195
I
See Footnote
Ordinary Shares
2019-05-28
4
C
0
636366
A
1529561
I
See Footnote
Ordinary Shares
2019-05-28
4
P
0
385714
14.00
A
1915275
I
See Footnote
Series A Preferred Shares
2019-05-28
4
C
0
625049
0
D
Ordinary Shares
893195
0
I
See Footnote
Series B1 Preferred Shares
2019-05-28
4
C
0
445323
0
D
Ordinary Shares
636366
0
I
See Footnote
S.R. One, Limited acquired 385,714 Common Stock of Bicycle Therapeutics Limited (the "Issuer") in connection with the Issuer's initial public offering.
The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").
/s/ Victoria Whyte
2019-05-29